Keya Medical
AI for Smarter Healthcare
CT-Derived FFR Analysis
Functional assessment of coronary artery disease from CCTA
DEEPVESSEL FFR is FDA-cleared, deep-learning-based software that calculates CT-derived FFR values from previously acquired CCTA data. It provides a color-coded 3D coronary model and branch-level FFR results to support qualified clinicians in evaluating the functional significance of coronary artery disease.
Coronary Plaque Analysis
Quantitative plaque assessment from CCTA
DEEPVESSEL Plaque is FDA-cleared, AI-assisted software that characterizes and quantifies coronary plaque and stenosis from previously acquired CCTA data. It provides quantitative measurements and visual clinical reports to support qualified clinicians in coronary artery assessment.
A New Category I CPT code for non-invasive FFR
Category I CPT Code
Starting January 1, 2024, medical practices will implement a new category I CPT code (75580) for non-invasive FFR estimates derived from coronary CT angiography software analysis.
The American College of Cardiology (ACC), American College of Radiology (ACR), and the Society of Cardiovascular Computed Tomography (SCCT) jointly proposed this change to the American Medical Association. It replaces four prior category III CPT codes.
Available in the USA, EMEA, China, Singapore
CE-Marked
2018
NMPA-Approved
2020
FDA-Cleared
2022
HSA-Certified
2023
Advantages
Precise
Comprehensive
Cost Saving
Physician Autonomy
Streamlined Workflow
Efficient
FFRCT and DVFFR have transformed my practice, allowing me to provide superior patient care and achieve better outcomes. I am sincerely grateful for this invaluable resource provided by Corazon Imaging.
News
COMPOSE-CT Validates DEEPVESSEL Plaque Against Expert Consensus
The multicenter COMPOSE-CT study demonstrated strong agreement between FDA-cleared DEEPVESSEL Plaque and Level III expert consensus for coronary plaque quantification and CAD-RADS stenosis categorization.
Comprehensive CCTA Assessment with DEEPVESSEL FFR and Plaque Analysis
Explore how quantitative plaque analysis and CT-FFR complement stenosis assessment in CCTA, including insights from COMPOSE-CT and the SCCT 2026 expert webinar.
Can FFR-CT Reduce Unnecessary Testing in Moderate CAD?
A recent study published in REC: Interventional Cardiology (2026) explores whether adding FFR-CT (DEEPVESSEL FFR) to standard CCTA can reduce testing in moderate CAD.
For healthcare professionals in the United States